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Summary Lonidamine is a substituted indazole carboxylic acid with a unique mechanism of action and early
clinical studies have reported anti-tumour activity.
In a phase II study 32 patients with previously treated advanced breast cancer were given Lonidamine in a
daily divided oral dose of 600 mg. Of 28 patients evaluable for response, three (11%) achieved a partial
response (4-24 + months) and three (11%) a minor response. Two patients have stable disease (> 3 months)
and 20 progressed. Toxicity was very mild. Sixteen (53%) of 31 patients had myalgia which lasted a median of
2 weeks. This was investigated with nuclear magnetic resonance spectroscopy in four patients but the changes
were unrelated to the degree of myalgia. No other major side-effect was seen, and no dose reduction was
required.
Lonidamine pharmacokinetics have been investigated in 17 patients 1 month after the start of therapy.
Lonidamine was detected in the plasma of all patients, but there was no clear relationship between
Lonidamine levels and clinical response or toxicity.
Lonidamine appears to be active against advanced breast cancer and its low toxicity would allow combina-
tion studies with chemotherapy.
The indazole carboxylic acid derivative Lonidamine (1-[2,4-
dichlorobenzyl]-l-H-indazole carboxylic acid), initially studied
for its antispermatogenic properties, was found to have
moderate anticancer activity in vivo against murine Lewis
lung carcinoma and sarcoma 180 tumours (Silvestrini, 1981).
In vitro studies in experimental tumour systems indicate that
Lonidamine inhibits oxygen consumption and aerobic glyco-
lysis; an effect that is associated with marked ultrastructural
mitochondrial changes (Floridi et al., 1981).
In phase I studies of oral Lonidamine the most frequent
side effects were myalgia, asthenia and somnolence (Weiss et
al., 1985). Myalgia was the dose limiting toxicity and occur-
red at a dose of 300-400 mgm-2 (Band et al., 1984; Band et
al., 1986; Weinerman et al., 1986). Of particular interest was
the complete lack of myelosuppression and alopecia. On the
basis of these studies Lonidamine, 600 mg daily in divided
doses, has been selected for phase II studies.
The pharmacokinetics of Lonidamine have been studied in
preclinical models (Segre & Catanese, 1981) but there is
relatively little pharmacokinetic data from patients (Young et
al., 1981; Besner et al., 1984). We have therefore measured
Lonidamine levels using a high performance liquid chromato-
graphy assay (HPLC) with fluorescence detection in 17
patients after 1 month of therapy. In the present study,
pharmacokinetic data have been analysed with respect to
patient characteristics and Lonidamine side-effects.
The aetiology of Lonidamine induced myalgia is unknown.
In view of the effects of Lonidamine on mitochondria we
have examined a small series ofpatients by in vivo 31P nuclear
magnetic resonance spectroscopy (31P NMRS) to investigate
a possible link between myalgia and high energy phosphate
metabolism. 31P NMR has been successfully applied to the
investigation of normal and diseased muscle metabolism
(Cresshull et al., 1981; Radda 1986). Most patients with
inherited mitochondrial myopathies demonstrate abnormal
high energy phosphate metabolism at rest (Radda et al.,
1985; Gadian et al., 1981; Eleff et al., 1984) and similar
changes might therefore be expected in patients taking
Lonidamine.
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Patients and methods
Patients
Between June 1988 and May 1989, 32 patients with histo-
logically proven advanced breast cancer were entered into the
study. Oral informed consent was obtained from all patients.
Patients were included provided they had measurable or
evaluable disease, performance status 0-2 (Zubrod scale),
age less than 75 years, no other previous or concomitant
malignant tumours except for skin carcinoma or in situ cer-
vical carcinoma, normal kidney function and no brain metas-
tases. Osteolytic bone lesions were considered evaluable, but
mixed or purely osteoblastic bone lesions and previously
irradiated sites were considered inevaluable for response.
Previous endocrine or chemotherapy was allowed but was
stopped at least 1 month before. Fifteen patients had
received endocrine therapy only whereas the remaining 16
patients had received both endocrine and chemotherapy. The
number of different types of endocrine therapy and chemo-
therapy is shown in Table I. Haematological recovery (white
blood count >3,500 mm-3, haemoglobin > lO g dl-',
platelets > 100,000 mm-3) from the effects of previous treat-
ment was mandatory. The median diseased-free interval from
time of diagnosis to development of metastases was 35
months (range 2-212 months). Three patients had locally
advanced disease only. Patient characteristics are shown in
Table I.
Investigations
Pretreatment Baseline investigations included physical
examination, full blood count and differential, electrolytes
and liver function tests, blood glucose and an electrocardio-
gram. Caliper measurement, X-rays, liver ultrasound and
isotopic bone scans were done if clinically indicated to
evaluate response to Lonidamine.
31 NMR spectroscopy 31P NMRS was carried out using a 1.5
Tesla Siemens Magnetom whole body NMR system. The
technique provides a non-invasive measure of high energy
intracellular phosphate metabolites, i.e. nucleoside triphos-
phates including ATP and phosphocreatine (PCr), and also
of their low energy degradation product, inorganic phosphate
(Pi). Nucleoside triphosphates produce three discrete
Br. J. Cancer (1991), 64, 593-597 '." Macmillan Press Ltd., 1991594 J.L. MANSI et al.
Table I Patient characteristics
Total number
Median age
Menopausal status
Oestrogen receptor status
Pretreatment
PS (WHO)
No. metastatic sites
Metastatic sites
Pre
Peri
Post
Positive
Negative
Unknown
ETa 1
2
3
4
CTa 1
2
3
0
1
2
2
>2
Soft tissue
Bone
Lung/pleura
Liver
Other
ET = endocrine therapy. CT = chemotherapy.
status. aNumber of different types of treatment.
32
53(41-
5
26
5
5
22
13
12
4
3
8
5
3
21
9
2
12
7
13
20
13
16
10
3
72)
PS = performance
resonant frequencies corresponding to each phosphorus atom
in the molecule. These are assigned gamma, alpha and beta
according to their specific chemical shifts. Of these only the
beta signal is purely triphosphate derived, predominantly in
the form of ATP. The relative proportions of these high and
low energy phosphates give an indication of the efficacy of
mitochondrial oxidative phosphorylation. Furthermore, in-
tracellular pH (pHi) can be determined from the resonant
frequency (chemical shift) of Pi (Gadian et al., 1982). Four
patients had 31P NMRS evaluations prior to and during
treatment with Lonidamine. The same region of muscle in
the high flexor group was chosen for each examination with
the patient measured at rest. Signal was obtained from the
chosen volume of interest using a conformal ISIS technique
(Sharp & Leach, 1989) in order to exclude possible con-
tamination from the adjacent tissue such as bone marrow.
Ratios of Pi/PCr and Pi/beta ATP together with pHi were
calculated for each 31P NMRS measurement.
Follow-up Patients were seen weekly for the first month and
monthly thereafter. Routine blood tests were checked at each
visit. Response assessment was made after 1 and 3 months on
treatment and subsequently 3 monthly unless clinically
indicated beforehand.
Dose and schedule
Lonidamine tablets were initially given by increments over 1
week to a final dose of 600 mg (150 mg in the morning,
150 mg in the afternoon and 300 mg at night). Treatment was
continued until evidence of disease progression unless there
was serious toxicity. Because of possible interactions patients
were told not to take salicylates during the study.
Pharmacokinetics
Pharmacokinetic studies were performed after 1 month of
treatment in 17 patients. Heparinised blood was taken at
time 0 (baseline), 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7 h after the 1st
and 2nd 150 mg doses and 2-hourly following the 3rd (300mg)
dose. Following separation samples were stored at - 20°C
until the analysis was performed.
The HPLC assay was based on that described by LeClaire
et al., 1983 with modifications including the use of fluores-
cence detection and quantification by the use of external
standards rather than an internal standard. The Lonidamine
assay and its validation are described in detail elsewhere
(Newell et al., 1991). The logarithm of the plasma concentra-
tion of Lonidamine was plotted against time and the peak
concentration following each dose was determined together
with the time at which this occurred. In addition the lowest
concentration during the 24 h study was recorded and, where
an exponential decline in plasma levels was observed, the
half-life calculated.
To investigate possible relationships between Lonidamine
pharmacokinetics and patient characteristics (sex, age, per-
formance status, prior treatment, liver metastases, urea,
creatinine, liver enzymes (alanine transaminase, gamma
glutamyl transaminase), albumin and total protein) and side-
effects (myalgia) at the time of sampling linear regression
(continuous data) or one way analysis of variance (discon-
tinuous data) studies were performed. Furthermore in two of
the responding patients the pharmacokinetics were repeated,
one at a time of progression.
Assessment ofresponse and toxicity
Patients were evaluable for response if they had received at
least 1 month of treatment. Patients who received continuous
steroids were not evaluable for response but evaluable for
progressive disease. Objective responses were defined accord-
ing to UICC criteria (Hayward et al., 1977). A category for
minor response was included where patients achieved greater
than 25% but less than 50% reduction of the product of the
two greatest perpendicular diameters of measurable lesions.
Complete, partial and minor responses had to be sustained
for at least 1 month and stable disease for at least 3 months.
The duration of response is measured from the beginning of
therapy to the date of disease progression.
Patients who received at least 1 week of treatment were
evaluable for toxicity. Toxicity was graded on a scale of 0-4
(0 = absent, 1 = mild and transient, 2 = moderate, affecting
daily activity although controlled symptomatically, 3 =
marked, not responding to symptomatic treatment, requiring
reduction of daily dose or stopping treatment, 4=life-
threatening).
Results
Response
Of the 32 patients entered into the study 28 were evaluable
for response. Two patients died and one had evidence of
progressive disease requiring chemotherapy before complet-
ing 4 weeks of treatment. One patient stopped treatment at 4
weeks because of general lethargy which was subsequently
found to be unrelated to Lonidamine; she was considered
inevaluable for response. The characteristics of responding
patients are shown in Table II. Three of 28 (11%) patients
achieved a partial response, 3 (11%) a minor response and 2
(7%) disease stabilisation (for 3 and 5 months). The estrogen
receptor status of the primary tumour was not known for
any of the responding patients. The remaining 20 patients
developed progressive disease within 3 months of treatment.
Toxicity
The toxicity data are summarised in Table III. One of the
patients who died had only received 4 days of Lonidamine
and was inevaluable for toxicity; there was no evidence that
this was treatment related.
The most frequent side-effect was myalgia. This occurred
in 16 (53%) patients and was generally mild lasting for 1 to 4
weeks in the majority of patients. Two patients had grade 2
myalgia but this was self-limiting within 1 and 3 weeks. No
patient required treatment with steroids.LONIDAMINE IN BREAST CANCER 595
Table II Characteristics of responding patients
Duration
Patient PS Metastases Previous treatment Response (months)
1 0 Lung Endocrine PR 15 +
2 0 ST Endocrine PR 4
3 0 ST, lung, Endocrine PR 16+
bone
4 0 ST Endocrine + chemotherapy MR 7 +
5 0 ST Endocrine + chemotherapy MR 8 +
6 0 ST Endocrine MR 9+
PR = partial response. MR = minor response. ST = soft tissue.
Table III Toxicity
Median duration
Toxicity Number % (weeks)
Myalgia 16 (53) 2
Weakness 1 (3) 1
Drowsiness 3 (10) 2
Change in hearing 1 (3) 2
Fever 1 (3) 2
Increased LFTs 1 (3)
Nausea 2 (6) 1
Lethargy 1 (3) 2
Other 6 (20) 1
No side-effects 9 (30)
The other toxicities were generally mild and self-limiting.
One patient developed abnormal liver function tests on two
occasions while on Lonidamine. However, these returned to
normal on treatment and the liver ultrasound was repeatedly
normal.
No patient required a dose reduction because of toxicity
and 9 (30%) had no side-effects.
3'NMR spectroscopy
Two of the four patients examined using 31P NMRS developed
myalgia at rest whilst receiving Lonidamine. Contrary to
expectation, the Pi/PCr and Pi/beta ATRP ratios tended to
be lower on treatment than with pre-treatment values. The
Pi/PCr ratio was reduced by 6% with no change in the
Pi/beta ATP in the patient with grade 2 myalgia and 39%
and 20% reductions respectively were observed in the patient
with grade 1 myalgia. In one of the two asymptomatic
patients the Pi/PCr and Pi/beta ATP ratios were reduced by
10% and 7% respectively and in the second the Pi became
undetectable after starting Lonidamine (Table IV).
The two symptomatic patients had pre-treatment resting
muscle pHi values of 7.1 After starting Lonidamine this fell
slightly to 7.0 in the patient with grade 1 myalgia. Of the two
asymptomatic patients, the muscle pHi in the first was 7.0
and did not change on Lonidamine. The pre-treatment pHi
was 7.1 in the second patient, but could not be measured on
treatment because the Pi peak became undetectable.
Pharmacokinetics
The peak plasma levels of Lonidamine after the first 150 mg
dose ranged from 7.6 to 3.8 iLg ml' (mean 15.5) and after
the second from 5.3 to 33.3 gig ml-' (mean 15.8). The
absolute range of the time at which the peaks were observed
was 0.5 to 4.0 h (mean 1.9) for the first and 0.5 to 4.1 h
(mean 2.0) for the second dose. The trough concentrations
for the entire 24 h study period ranged from 1.7 to
10.8 pg ml-' (mean 5.1) and for the courses where an
exponential decline in Lonidamine levels was observed the
range of plasma half-lives was 2.5 to 7.8 h (mean 3.9). These
data indicate that Lonidamine had been absorbed in all
patients. Examples of plasma Lonidamine concentration vs
time curves are shown in Figure 1.
Increasing age was the only patient characteristic which
related to Lonidamine pharmacokinetics. This was a weak
positive linear correlation with peak concentration (r = 0.45,
P = 0.02). The other patient characteristics, biochemistry and
myalgia were unrelated to the pharmacokinetics of the drug.
Lonidamine pharmacokinetics were studied in three
patients who responded to therapy. As shown in Figure la,
the plasma levels in the responding patients were not clearly
different from those who did not respond, three examples
being given in Figure lb.
In addition to the major Lonidamine peak a number of
other peaks were seen in HPLC chromatograms which were
not detected in pre-treatment samples. The time course for
the change in plasma levels of certain of these additional
components parallel that of Lonidamine (Figure 2) and hence
they are likely to be Lonidamine derived.
Discussion
This phase II study of Lonidamine in advanced breast cancer
confirms other reports of activity in pre-treated patients. In a
study by Band et al. (1986) 5 of 30 (17%) patients achieved a
partial response, but three of these patients were given
Table IV In vivo 13P NMRs: changes in muscle high energy phosphate metabolism
Patient Myalgia Pi/beta ATP
no. (grade) Pi/PCr ratio % Change ratio % Change
(1)
Pre-Lonidamine 0.24 0.68
On Lonidamine 2 0.22 - 6% 0.68 0%
(2)
Pre-Lonidamine 0.18 0.44
On Lonidamine 1 0.11 - 39% 0.35 - 20%
(3)
Pre-Lonidamine 0.22 0.55
On Lonidamine 0 0.20 - 10% 0.51 - 7%
(4)
Pre-Lonidamine 0.09 0.28
On Lonidamine 0 Pi undetectable Pi undetectable596 J.L. MANSI et al.
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Figure 1 Plasma Lonidamine concentrations following oral
administration. Lonidamine concentrations were determined after
approximately 1 month on therapy. a, Plasma levels in three
patients who responded to Lonidamine (0..., partial response;
0 , minor response; 0--, mixed response, i.e. partial response
in soft tissue and no change in a lung deposit). b, Plasma levels of
Lonidamine in three patients who did not respond to Lonidamine
therapy.
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Figure 2 Time course for levels of fluorescent components
detected in the plasma of a patient treated with Lonidamine.
Levels are given as arbitrary peak area units derived from the
HPLC chromatograms. Key as follows, showing values for
relative HPLC retention volume (Lonidamine = 1): A 0.6; 0 1.0
- Lonidamine; 0 1.7; M 1.9; A 2.1; 0 2.3.
steroids to alleviate myalgia. Pronzato et al. (1989) have
recently reported a response rate of 16% in 25 evaluable
patients; no steroids were given in this study and it is
therefore directly comparable to ours. Combining partial and
minor responses together increases the response rate to 22%.
Toxicity was minimal and generally transient. In common
with other studies myalgia was the most frequent side-effect
(Band et al., 1986; Pronzato et al., 1989). Although in vivo
31P NMRS has confirmed abnormal high energy phosphate
metabolism in most patients with inherited mitochondrial
myopathies at rest (Gadian et al., 1981), in the present study
similar techniques have failed to demonstrate abnormalities
even though ultrastructural mitochondrial changes are
known to occur in vitro (Floridi et al., 1981). The reduction
in both Pi/PCr and Pi/beta ATP ratios found in our patients
has also been shown to occur in resting Wistar rat skeletal
muscle (Griffiths, J., personal communication). Furthermore,
the magnitude of the changes observed does not appear to be
related to the presence or absence of symptoms. To date we
have no satisfactory explanation for these unpredicted
findings. However, possible reasons for loss of intracellular Pi
signal include drug induced cellular loss, an apparent fall
resulting from sequestration of Pi into an NMR invisible
pool, and broadening and flattening of the Pi peak due to pH
heterogeneity (Madden et al., 1990). However, in common
with our results the resting pHi is frequently normal in
patients with mitochondrial myopathy (Gadian et al., 1981).
Myalgia may, however, result from changes in extracellular pH
which would not be detected by 31P NMRS. In this respect
Lonidamine is known to stimulate lactate production by
normal cells in vitro (Floridi et al., 1989), an effect which
would not be detected using the NMRS technique employed
in this study. It must be noted, however, that this work is
preliminary and more patients would be needed to confirm
these hypotheses.
The pharmacokinetic data indicate that in all the patients
studied there was absorption following oral administration.
The peak and trough concentrations together with the half-
life are in general agreement with previous investigations
(Young et al., 1981; Besner et al., 1984). Attempts to relate
Lonidamine pharmacokinetics to either patient characteristics
at the time of treatment or to side-effects revealed only one
weak correlation. That is, the peak concentration tended to
be higher in older patients. However, the small magnitude of
this effect is such that it is unlikely to be of clinical
significance.
No conclusions could be drawn on a possible correlation
between tumour response and plasma concentrations, because
of the small number of patients responding. Thus the present
study does not confirm the suggestion of Besner et al. (1984)
that the trough level of Lonidamine is lower (<3 1tg ml-') in
unresponsive patients than in responding individuals. In
agreement with the present results, De Angelis et al. (1989)
failed to detect any difference in Lonidamine plasma levels in
patients with brain metastases who did or did not respond to
the drug when given with radiotherapy.
The presence of a number of fluorescent components other
than Lonidamine in the HPLC analyses of plasma from
patients receiving the drug suggests that Lonidamine is
metabolised. Thus the components were not present in
pretreatment samples and the levels of certain of the com-
ponents paralleled those of Lonidamine. Further experiments
(Newell et al., 1991) have shown that in some patients the
levels of Lonidamine increase after B-glucuronidase treat-
ment further suggesting that at least one of the components
may be a glucuronic acid conjugate of the parent compound
(Figure 2, relative retention volume = 0.8). The other com-
ponents which are not sensitive to B-glucuronidase (Caldwell
& Hutt, 1986) may represent amino acid conjugates of
Lonidamine. It is possible that these components may be of
clinical significance.
Lonidamine has a unique mechanism of action and spec-
trum of toxicity. In vitro studies suggest that it may inhibit
recovery from potentially lethal damage from radiation and
cytotoxic drugs. The place for Lonidamine in cancer therapy
may therefore be in combination with cytotoxics or con-
comitant radiotherapy. Previous studies of Lonidamine in
combination with chemotherapy in other tumour types such
as non-small cell lung cancer (Breau et al., 1988), malignant
glioma (Carapella et al., 1985), and bladder cancer (Gian-
notti et al., 1984) have not shown any potentiation of side-
effects. Moreover, when Adriamycin was given prior to
Lonidamine in tumour bearing mice a synergistic anti-
tumour effect was seen (Zupi et al., 1986). Preliminary results
using combination chemotherapy (5-fluorouracil, Adriamycin
and cyclophosphamide) with and without Lonidamine has
shown an increased response rate with the addition of
Lonidamine (63% vs 44%, P = 0.002) and a longer median
time to progression (39 weeks vs 25 weeks, P = 0.002)
(Calabresi et al., 1990). Thus Lonidamine in combination
with chemotherapy may be a promising treatment option.
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